Mauricio Burotto

Líneas de investigación

• Inmuno-oncología e investigación clínica en tumores específicos como cáncer de pulmón
• renal y melanoma.

Tus publicaciones

• PRIMARY ADRENAL INSUFFICIENCY DURING IMMUNE CHECKPOINT INHIBITOR TREATMENT Autores: Salinas, C., Renner, A., Rojas, C., Samtani, S., Burotto, M., Año: 2020 Link: https://doi.org/10.1159/000507652
• RECOMMENDATIONS FOR DETECTION, PRIORITIZATION, AND TREATMENT OF THORACIC ONCOLOGY PATIENTS DURING THE COVID-19 PANDEMIC Autores: Arrieta, O., Cardona, F., Lara-Mejía, L., Heredia, D., Barrón, F., Zatarain-Barrón, L., Lozano, F., de Lima, C., Maldonado, F., Corona-Cruz, F., Ramos, M., Cabrera, L., Martin, C., Corrales, L., Cuello, M., Arroyo-Hernández, M., Aman, E., Bacon, L., Baez, R., Benitez, S., Botero, A., Burotto, M., Caglevic, C., Ferraris, G., Freitas, H., Kaen, L., Lamot, S., Lyons, G., Mas, L., Mata, A., Mathias, C., Muñoz, A., Patane, K., Oblitas, G., Pino, L., Raez, E., Remon, J., Rojas, L., Rolfo, C., Ruiz-Patiño, A., Samtani, S., Viola, L., Viteri, S., Rosell, R., Año: 2020 Link: https://doi.org/10.1016/j.critrevonc.2020.103033
• RESULTS OF A DOSE-FINDING PHASE 1B STUDY OF SUBCUTANEOUS ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NONSMALL CELL LUNG CANCER Autores: Felip, E., Burotto, M., Zvirbule, Z., Herraez-Baranda, A., Chanu, P., Kshirsagar, S., Maiya, V., Chan, P., Pozzi, E., Marchand, M., Monchalin, M., Tanaka, K., Tosti, N., Wang, B., Restuccia, E., Año: 2021 Link: https://doi.org/10.1002/cpdd.936
• NIVOLUMAB PLUS CABOZANTINIB VERSUS SUNITINIB FOR ADVANCED RENAL-CELL CARCINOMA Autores: Choueiri, K., Powles, T., Burotto, M., Escudier, B., Bourlon, T., Zurawski, B., Juárez, M., Hsieh, J., Basso, U., Shah, Y., Suárez, C., Hamzaj, A., Goh, C., Barrios, C., Richardet, M., Porta, C., Kowalyszyn, R., Feregrino, P., Zolnierek, J., Pook, D., Kessler, R., Tomita, Y., Mizuno, R., Bedke, J., Zhang, J., Maurer, A., Simsek, B., Ejzykowicz, F., Schwab, M., Apolo, B., Motzer, J., Año: 2021 Link: https://doi.org/10.1056/NEJMoa2026982
• NIVOLUMAB PLUS IPILIMUMAB VERSUS SUNITINIB FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA Autores: Albiges, L., Tannir, M., Burotto, M., McDermott, D., Plimack, R., Barthélémy, P., Porta, C., Powles, T., Donskov, F., George, S., Kollmannsberger, K., Gurney, H., Grimm, O., Tomita, Y., Castellano, D., Rini, I., Choueiri, K., Saggi, S., McHenry, B., Motzer, J., Año: 2020 Link: https://doi.org/10.1136/esmoopen-2020-001079
• POTENTIAL USE OF N-3 PUFAS TO PREVENT OXIDATIVE STRESS-DERIVED OTOTOXICITY CAUSED BY PLATINUM-BASED CHEMOTHERAPY Autores: Cortés Fuentes, A., Burotto, M., Retamal, A., Frelinghuysen, M., Caglevic, C., Gormaz, G., Año: 2020 Link: https://doi.org/10.1016/j.freeradbiomed.2020.07.035
• NIVOLUMAB + IPILIMUMAB (N+I) VS SUNITINIB (S) DANS LE TRAITEMENT DE PREMIRE LIGNE DU CARCINOME RÉNAL AVANCÉ (ARCC) DANS L`ÉTUDE CHECKMATE 214 Autores: Albiges, L., Tannir, N., Burotto, M., Mcdermott, D., Plimack, E., Barthélémy, P., Porta, C., Powles, T., Donskov, F., George, S., Kollmannsberger, C., Gurney, H., Grimm, M., Tomita, Y., Castellano, D., Rini, B., Choueiri, T., Shally Saggi, S., Mchenry, M., Motzer, R., Año: 2020 Link: https://doi.org/10.1016/j.purol.2020.07.155
• PREFERENCE FOR THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS INJECTION IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER (PHRANCESCA) Autores: O`Shaughnessy, J., Sousa, S., Cruz, J., Fallowfield, L., Auvinen, P., Pulido, C., Cvetanovic, A., Wilks, S., Ribeiro, L., Burotto, M., Klingbiel, D., Messeri, D., Alexandrou, A., Trask, P., Fredriksson, J., Machackova, Z., Stamatovic, L., Korbenfeld, E., Nadal, J., Pinczowski, H., Cruz, J., Sousa, G., Goncalves, C., Guilgen, G., Jekunen, A., Yeo, W., Cheng, K., Razeq, A., Karak, F., Farhat, F., Huerta, C., Jaime, M., Feregrino, J., Castillo-Fernandez, O., Alcedo, C., Dionisio, M., Bujassoum, S., Bakhraibah, H., Lescure, R., Wendt, C., Margolin, S., Bjrneklett, G., Cairo, M., Dakhil, S., Le-Lindqwister, N., Ma, L., McIntyre, J., O`Shaughnessy, J., Vukelja, J., Richards, D., Año: 2021 Link: https://doi.org/10.1016/j.ejca.2021.03.047
• NEOADJUVANT IMMUNOTHERAPY FOR MUSCLE INVASIVE UROTHELIAL BLADDER CARCINOMA Autores: Renner, A., Burotto, M., Valdes, M., Roman, C., Walton-Diaz, A., Año: 2021 Link: https://doi.org/10.1177/17562872211029779
• MRI AND TARGETED BIOPSY ESSENTIAL TOOLS FOR AN ACCURATE DIAGNOSIS AND TREATMENT DECISION MAKING IN PROSTATE CANCER Autores: Samtani, S., Burotto, M., Roman, C., Cortes-Herrera, D., Walton-Diaz, A., Año: 2021 Link: https://doi.org/10.3390/diagnostics11091551
• FIRST-LINE NIVOLUMAB PLUS IPILIMUMAB VERSUS SUNITINIB IN PATIENTS WITHOUT NEPHRECTOMY AND WITH AN EVALUABLE PRIMARY RENAL TUMOR IN THE CHECKMATE 214 TRIAL Autores: Albiges, L., Tannir, M., Burotto, M., McDermott, D., Plimack, R., Barthélémy, P., Porta, C., Powles, T., Donskov, F., George, S., Kollmannsberger, K., Gurney, H., Grimm, O., Tomita, Y., Castellano, D., Rini, I., Choueiri, K., Leung, D., Saggi, S., Lee, W., McHenry, B., Motzer, J., Año: 2021 Link: https://doi.org/10.1016/j.eururo.2021.10.001
• CURRENT LANDSCAPE OF IMMUNOTHERAPY TRIALS INVOLVING THE PROGRAMMED CELL DEATH PROTEIN 1/PROGRAMMED DEATH-LIGAND 1 AXIS IN INTRATHORACIC TUMORS Autores: Kareff, A., Samtani, S., Burotto, M., Prasad, V., Kim, C., Año: 2021 Link: https://doi.org/10.1016/j.jtocrr.2021.100149
• CONDITIONAL SURVIVAL AND LONG-TERM EFFICACY WITH NIVOLUMAB PLUS IPILIMUMAB VERSUS SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA Autores: Motzer, J., McDermott, F., Escudier, B., Burotto, M., Choueiri, K., Hammers, J., Barthélémy, P., Plimack, R., Porta, C., George, S., Powles, T., Donskov, F., Gurney, H., Kollmannsberger, K., Grimm, O., Barrios, C., Tomita, Y., Castellano, D., Grünwald, V., Rini, I., McHenry, B., Lee, W., McCarthy, J., Ejzykowicz, F., Tannir, M., Año: 2022 Link: https://doi.org/10.1002/cncr.34180